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PHP1
EFFECT OF PRESCRIPTION COPAY ON MEDICATION
UTILIZATION
Gause D, Doyle JJ, Plauschinat C
Novartis Pharmaceuticals, East Hanover, NJ, USA
OBJECTIVE: To assess impact of change in prescription copay
on change in medication utilization among patients taking three
common brand name medications: atorvastatin for dyslipide-
mia, pioglitazone for diabetes, or valsartan for hypertension.
METHODS: The Medstat MarketScan database was used to
identify patients taking a study drug (atorvastatin, pioglitazone,
or valsartan) in both 2003 and 2004. Patients had to have
continuous pharmacy coverage, at least one ﬁll in each year, and
be <65 years of age. The total copay for study drug was divided
by the total number of prescription ﬁlls to calculate average
copay for each patient in each year. Regression and partial cor-
relation analysis was used to estimate the association between
changes in copay and days supply, adjusting for age and gender.
RESULTS: Among 9342 valsartan patients, 4622 (49%) patients
had an increase in average copay and for these patients there was
on average 32 fewer days on drug in 2004 compared to valsartan
patients without an increase in copay (Spearman Rho = -0.14,
p-value < 0.01). There was also a negative association between
copay and days supply in patients receiving atorvastatin or
pioglitazone: 15 days less on pioglitazone and 18 days less on
atorvastatin for patients having an increase in average copay for
2004. Among patients using mail order prescriptions with ﬁlls
for >30 day supply the impact of copay on days supply was less
but still statistically signiﬁcant. CONCLUSION: Policy and
beneﬁt decision makers need to consider the impact of patient
copay on persistence for chronic diseases such as diabetes, hyper-
lipidemia, and hypertension.
PHP2
ADHERENCETO EVIDENCE-BASED GUIDELINES AND
MEDICATION COMPLIANCE FOR MULTIPLE CHRONIC
DISEASES IN A MANAGED CARE DATABASE
Burch SP, Priest JL, Cook CL, Cantrell CR
GlaxoSmithKline, Research Triangle Park, NC, USA
OBJECTIVE: To examine both adherence to treatment guide-
lines and medication compliance for commercially insured
patients with common chronic conditions including asthma,
chronic obstructive pulmonary disease (COPD), congestive heart
failure (CHF), coronary artery disease (CAD), depression, diabe-
tes, hyperlipidemia, and hypertension. METHODS: A retrospec-
tive cohort analysis of claims data was conducted using the
IHCIS Impact National Benchmark database representing >45
million lives. Patients were selected with evidence of disease
condition(s) between 2002 and 2006 who had 6 months of
data available post identiﬁcation with coverage through Decem-
ber 31, 2006. All analyses were conducted in 2006 and all costs
were annualized. Proportion of Days Covered was measured to
calculate compliance (between ﬁrst and last ﬁll) and persistence
(ﬁrst ﬁll through end of year) using an 80% cutoff. RESULTS:
For diabetes patients, 54% received no HbA1c test in 2006 and
only 33% received the ADA recommended 2 tests (measure
required patients to be continuously eligible during 2006 and
have prior evidence of diabetes). The percentage of patients
ﬁlling any acceptable disease speciﬁc prescription in 2006 was
80% for CHF, 68% for CAD, 60% for diabetes, 57% for depres-
sion, 44% for asthma and 36% for COPD. Of patients ﬁlling
medication, compliance ranged from 75% for diabetes and CHF
down to 49% and 36% for COPD and asthma respectively.
Persistence rates ranged from 77% for CAD to 23% for asthma.
CHF, COPD and CAD had the most expensive per-patient-per-
year total medical and pharmacy costs averaging $24,540,
$14,169, and $13,627 respectively. CONCLUSION: Across all
eight conditions, the percent of patients ﬁlling any acceptable
medication per treatment guidelines was low. Of those ﬁlling
medication, compliance and persistence rates were sub-optimal.
With the prevalence of chronic diseases increasing and the cost
associated rising dramatically, improvements in care per guide-
lines and medication compliance could potentially beneﬁt
patients, reduce costs and improve outcomes.
PHP3
ISTHERE AN ACCEPTABLE LEVEL OF MEDICATION
ADHERENCE? A REVIEW OF RETROSPECTIVE ADHERENCE
EVALUATION STUDIES
Visaria J, Seoane-Vazquez E, Schwartzbaum J, Szeinbach SL
The Ohio State University, Columbus, OH, USA
OBJECTIVE: The rationale for selection of a cut-point between
acceptable and unacceptable medication adherence has not been
previously evaluated. The objectives of this study were to
describe the dichotomized measures for medication adherence
and assess the rationale for selection of the cut-point.
METHODS: A systematic Medline review and examination of
studies assessing adherence using pharmacy claims from January
1997–June 2007 was performed. Studies containing partial or
incomplete methods for measuring adherence were excluded. A
sub-analysis of articles was conducted to determine the rationale
for selection of the cut-point. RESULTS: The review identiﬁed 98
studies with 103 measures of adherence. These studies investi-
gated adherence to cardiovascular drugs (39.8%), hormones and
synthetic substitutes (33.0%) and others (28.2%). The following
types of measures were used: medication possession ratio (MPR)
(45.6%), ﬁxed gap between reﬁlls (38.8%), proportion of days
covered (7.8%) and others (7.8%). Dichotomous measures were
used by 32.0% of the studies. A cut point was speciﬁed for
35.9% measures of adherence. The mean cutoff value was
76.0%  12.9%; with a median of 80.0%, and a range of
20.0%–90.0%. The sub-analysis contained 28 articles of which
35.7% refer to cut-points derived from previous clinical studies,
21.4% selected the cutpoint arbitrarily and 14.3% offered no
explanation, 7.1% provided clinical evidence, and 7.1%
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mentioned a reference that actually indicated that dichotomiza-
tion of the continuous adherence variable was inappropriate.
CONCLUSION: MPR and gap between reﬁlls were the most
commonly used measures of medication adherence. Almost one
third of the studies used dichotomous measures. A medication
adherence of 80% of the therapy was typically indicated as the
cut-point between adherence and non-adherence. There is no
accepted clinical or pharmacological rationale for medication
adherence threshold selection. The use of continuous variables to
measure medication adherence is recommended.
PHP4
THE IMPACT OF COPAYMENTS OR BRAND NAMED DRUG ON
MEDICATION PERSISTENCE
Wu J1, Nichol MB1, Knight TK1, Mahoney J2, Berman C2
1University of Southern California, Los Angeles, CA, USA,
2Pitney Bowes Inc, Stamford, CT, USA
OBJECTIVE: To examine the impact of copayments or brand
named drug as well as other factors on medication persistence
from a large U.S. employer. METHODS: We analyzed medical
and pharmaceutical claims data from 2002 through 2006 for
new users prescribed a single agent for either three antihyperten-
sive (angiotensin converting enzyme inhibitors, beta blockers,
and calcium blockers) or two anti-diabetic (biguanides and sul-
fonylureas) therapeutic classes. Nonpersistence with medication
was measured using three methods: medication possession ratio
(MPR) <0.8; number of days to the ﬁrst drug coverage gap of
15 days; and number of days to drug discontinuation (90
days gap). Logistic regression and Cox proportional hazard
models were performed to evaluate the association between the
potential risk factors and the likelihood of medication nonper-
sistence. RESULTS: A total of 1422 members with 12 months
claim data following the ﬁrst drug ﬁlled were identiﬁed. Fifty-
four percent were male with a mean age 52.8  8.0 years, and
44% initially used a brand named drug. The logistic regression
results revealed that increasing age per year (OR = 0.966; 95%
CI = 0.952–0.979), PPO (OR = 0.424; CI = 0.261–0.689) or
HMO insurance (OR = 0.440; CI = 0.262–0.739) as compared
to conventional fee for service coverage were less likely to have
MPR < 0.8. Management workers (OR = 1.475; CI = 1.113–
1.954) were more likely to have MPR < 0.8. MPR < 0.8 was not
associated with use of an initial brand named drug, comorbidi-
ties, or health care utilization in the six months prior to initiating
medication therapy. The Cox models showed that the risk for
a gap increased 1.1% (HR = 1.011, CI = 1.004–1.019), and
medication discontinuation increased 0.9% (HR = 1.009,
CI = 1.003–1.014) with each $1 increase in initial drug copay-
ments. CONCLUSION: Younger employees, management
workers, conventional fee for service insurance coverage, and an
increase in initial copayments are factors predictive of greater
risk for noncompliance with medications. These data may be
helpful for employers when making drug beneﬁt design decisions.
PHP5
ADHERENCE AND SWITCHINGWITH DRUGS USED FORTHE
PROPHYLAXIS OF ORGAN REJECTION
Varasteh LT, Pedan A,Asumeng-Denteh E
Adheris, Inc, Burlington, MA, USA
OBJECTIVE: The purpose of this study was to quantify the
extent of nonadherence and to determine the rate of switching
across organ rejection drugs. METHODS: Blinded prescription
data from 35 national retail pharmacy chains was analyzed for
13,250 patients taking sirolimus, cyclosporine, and tacrolimus.
Cumulative drug consumption (total days supply) during the one
year follow up period was employed as the measure of adher-
ence. Kaplan Meier estimates of survival (persistence) curves
were used to assess the time to discontinuation and to calculate
the one-year rate of discontinuation. Baseline patient character-
istics, including age, gender, geographic region, median income,
index quantity dispensed, population density, co-pay, and index
reﬁll and days supply prescribed were analyzed. RESULTS:
Adherence data across these drugs showed that sirolimus,
cyclosporine, and tacrolimus patients on average obtained 5.5
(4.5), 5.2 (5.4), and 6.5 (5.3) ﬁlls, and 170.8 (132.9),
159.2 (163.96), and 194.8 (159.6) days supply of medication
over 12 months, respectively. At day 60, 41% of sirolimus, 44%
of tacrolimus, and 52% of cyclosporine patients discontinued
therapy. After 6 months, 68% of tacrolimus and sirolimus and
77% of cyclosporine patients discontinued therapy. The rate of
switching to another agent was 6.5% for sirolimus, 1.4% for
tacrolimus, and 1.1% for cyclosporine at month 6, and 10.9%,
2.3%, and 1.8% at month 12, respectively. CONCLUSION:
Even though organ transplant drugs are vital for transplant
patients, 68% to 77% of patients discontinue therapy after 6
months. Research has showed that nonadherence to immunosup-
pressive therapy is the leading cause of organ rejection, organ
loss, and death. Efforts to maintain patients on these drugs are
needed in the beginning of and throughout treatment to avoid
organ rejection.
PHP6
PREDICTORS OF NONCOMPLIANT COST-CUTTING
BEHAVIORS AMONG ADULTS INTHE UNITED STATES
Kannan H, Bolge SC
Consumer Health Sciences, Princeton, NJ, USA
OBJECTIVE: To determine the demographic, insurance, and
health status predictors of noncompliant cost-cutting behavior
among U.S. adults. METHODS: Data were from quarters one
and two of the 2007 National Health and Wellness Survey
(NHWS), an internet-based study of the health care attitudes,
behaviors, disease states, and outcomes of a demographically
representative sample of adults age 18+. Noncompliant cost-
cutting behaviors were deﬁned as taking less medication than
prescribed, cutting tablets in half, or buying fewer tablets. Logis-
tic regression analysis was used to determine the demographic,
insurance, and health status predictors of noncompliant cost-
cutting behavior. RESULTS: Of the 42,010 NHWS respondents,
12% reported some noncomplaint cost-cutting behavior, more
speciﬁcally 7% reported taking less medication than prescribed,
6% reported cutting tablets in half, and 2% reported buying
fewer tablets. Signiﬁcant predictors of greater likelihood of
noncompliant cost-cutting behavior include being non-white
(OR = 1.182, p < 0.001), having a college degree (OR = 1.094,
p = 0.009), having individual or family insurance purchased
directly (OR = 1.300, p < 0.001), purchasing medications
outside the U.S. (OR = 3.862, p < 0.001), number of physical
comorbid conditions (OR = 1.176, p < 0.001), having a psychi-
atric condition (OR = 1.620, p < 0.001), currently smoke
(OR = 1.137, p < 0.001), and body mass index (OR = 1.006,
p = 0.007). Signiﬁcant predictors of lesser likelihood of noncom-
pliant cost-cutting behavior include age (OR = 0.996, p = 0.001),
having insurance through the Veteran’s Administration
(OR = 0.514, p < 0.001), and having Rx coverage (OR = 0.808,
p < 0.001). Gender, marital status, annual income greater than
$50,000, number of adults in household, and insurance through
employer, Medicaid, or Medicare were not signiﬁcant predictors
of non-compliant cost cutting behavior. CONCLUSION: There
are several signiﬁcant predictors of noncompliant cost-cutting
behavior. Knowing these predictors may help in targeting cost
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